Botulinum toxin products — medical coverage criteria
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage, prior authorization, quantity limits, and continuation criteria for botulinum toxin products (preferred: Botox, Dysport, Xeomin) across neurologic and related indications for Community-Care members in North Carolina.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Therapy
Covered when ALL of the following indication-specific criteria are met
Continuation Therapy
Covered when ALL of the following are met for continuation of chronic migraine therapy
Products used for cosmetic purposes are excluded from plan benefits. Examples of excluded cosmetic indications include onabotulinumtoxinA (Botox Cosmetic) when used for aesthetic facial lines such as moderate to severe glabellar lines, lateral canthal lines, platysma bands, and forehead lines. PrabotulinumtoxinA (Jeuveau) for temporary improvement of moderate to severe glabellar lines is also excluded. IncobotulinumtoxinA (Xeomin) used for the appearance of upper facial lines (glabellar, horizontal forehead, or lateral canthal lines) and daxibotulinumtoxinA-lanm (Daxxify) for temporary improvement of moderate to severe glabellar lines are likewise not covered under the cosmetic use exclusion.
Use of botulinum toxin for cosmetic or aesthetic indications described in this policy is considered not covered. Specific excluded products and labeled aesthetic uses include: onabotulinumtoxinA (Botox Cosmetic) for facial lines (glabellar, lateral canthal, platysma, forehead), prabotulinumtoxinA (Jeuveau) for glabellar lines, incobotulinumtoxinA (Xeomin) for upper facial lines, and daxibotulinumtoxinA-lanm (Daxxify) for glabellar lines.
Billing Codes and Quantity Limits
Prior Authorization, Step Therapy, and Documentation
Prior Authorization Required
Prior authorization is required for all botulinum toxin therapies prior to administration. Requests must document the specific indication, relevant diagnostic information, prior trials or contraindications of alternative botulinum products when applicable, and the proposed dosing interval. Authorization will be limited to indication-specific quantity and frequency limits (see Appendix 1).
- All botulinum toxin products require prior authorization.
- Include diagnosis, indication-specific documentation, and planned dose/frequency.
- Approval limited to Appendix 1 quantity/frequency limits.
Step Therapy Between Botulinum Products
Step therapy requirements apply when onabotulinumtoxinA (Botox) is requested for many indications. Providers must document trials of preferred alternative botulinum toxin products (e.g., incobotulinumtoxinA/Xeomin and/or abobotulinumtoxinA/Dysport) that were ineffective, contraindicated, or not tolerated per indication-specific criteria.
- Cervical dystonia: trials of Xeomin and Dysport required (unless patient aged 16–17).
- Blepharospasm: trial of Xeomin required (exceptions for ages 12–17).
- Upper limb spasticity: trials of Xeomin and Dysport required.
- Lower limb spasticity: trial of Dysport required.
Pediatric Weight and Quantity Documentation
For pediatric members (<18 years) where approved, weight must be provided to determine appropriate quantity dosing. Approvals and quantity limits for pediatric patients are weight-based where indicated; reference Appendix 1 and the product package insert for dose-per-site and weight-based charts.
- A weight is required for pediatric approvals for chronic sialorrhea, neurogenic detrusor overactivity, and upper/lower limb spasticity.
- Appendix 1 and product inserts contain pediatric unit limits and weight-based dosing charts.
Cosmetic Use Excluded from Coverage
Botulinum toxin products used for cosmetic purposes are excluded from coverage. This includes but is not limited to Botox Cosmetic, Jeuveau (prabotulinumtoxinA), Xeomin for upper facial lines, and Daxxify (daxibotulinumtoxinA-lanm) when used for temporary improvement of moderate to severe glabellar, forehead, or lateral canthal lines and platysmal bands.
- Cosmetic indications (e.g., glabellar lines, lateral canthal lines, forehead lines, platysma bands) are not covered.
- Specific excluded products include onabotulinumtoxinA (Botox Cosmetic), prabotulinumtoxinA (Jeuveau), incobotulinumtoxinA (Xeomin) for upper facial lines, and daxibotulinumtoxinA-lanm (Daxxify).
Clinical Background
Botulinum toxin products are used across specialties for both therapeutic and aesthetic purposes; however, this policy distinguishes clinical indications from cosmetic uses. Therapeutic uses (covered when criteria are met) include neurologic and urologic conditions such as dystonias, spasticity, chronic sialorrhea, blepharospasm, chronic migraine prevention, and bladder dysfunction. By contrast, products or formulations approved and used primarily for improving facial appearance (for example, Botox Cosmetic, Jeuveau, Xeomin for upper facial lines, and Daxxify for glabellar lines) fall under the policy’s cosmetic exclusion and are not covered.
Definitions and Diagnostic Thresholds
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.